Cabozantinib Improves Outcomes Over Erlotinib in Advanced NSCLC

Cabozantinib alone or in combination with erlotinib improved survival outcomes among patients with advanced EGFR wild-type non –small-cell lung cancer.

Source: CancerNetwork - November 23, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news